These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26677712)

  • 21. Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors.
    Chang Y; Zhou S; Li E; Zhao W; Ji Y; Wen X; Sun H; Yuan H
    Eur J Med Chem; 2017 Jan; 126():143-153. PubMed ID: 27750148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK; Ghate M; Goel A
    J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of in Silico Models for Predicting P-Glycoprotein Inhibitors Based on a Two-Step Approach for Feature Selection and Its Application to Chinese Herbal Medicine Screening.
    Yang M; Chen J; Shi X; Xu L; Xi Z; You L; An R; Wang X
    Mol Pharm; 2015 Oct; 12(10):3691-713. PubMed ID: 26376206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viability of developing CETP inhibitors.
    Sirtori CR; Mombelli G
    Cardiovasc Ther; 2008; 26(2):135-46. PubMed ID: 18485135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential synergistic effects of Chinese herbal prescription FTZ components detected in blood towards hepatic lipid-modulating targets.
    Wang L; Tao W; Luo D; Hu Y; Bei W; Guo J
    Complement Ther Med; 2014 Oct; 22(5):887-93. PubMed ID: 25440380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of selective farnesoid X receptor agonists for the treatment of hyperlipidemia from traditional Chinese medicine based on virtual screening and in vitro validation.
    Chen X; Lu F; Luo G; Ren Y; Ma J; Zhang Y
    J Biomol Struct Dyn; 2020 Sep; 38(15):4461-4470. PubMed ID: 31842697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Method of traditional Chinese medicine formula design based on 3D-database pharmacophore search and patent retrieval].
    He YS; Sun ZY; Zhang YL
    Zhongguo Zhong Yao Za Zhi; 2014 Nov; 39(22):4411-7. PubMed ID: 25850277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
    Okamoto H; Yonemori F; Wakitani K; Minowa T; Maeda K; Shinkai H
    Nature; 2000 Jul; 406(6792):203-7. PubMed ID: 10910363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Virtual screening study of cathepsin S natural inhibitor].
    Gao Y; Shen J; Liu HB
    Zhongguo Zhong Yao Za Zhi; 2019 Mar; 44(6):1201-1207. PubMed ID: 30989984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
    Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.